Compare Trekor Metals Limited Common Shares (TGB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trekor Metals Limited Common Shares vs Tango Therapeutics Inc. — how do they compare? Trekor Metals Limited Common Shares trades at $8.2 (market cap $3.12B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Trekor Metals Limited Common Shares is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Trekor Metals Limited Common Shares for 4 Days and Tango Therapeutics Inc. for 0 Days on average.
| TGB | TNGX | |
|---|---|---|
Market Cap | $3.12B | $3.75B |
Volume | 3,598,372 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $9.68 | $32.90 |
52-Week Low | $3.75 | $7.50 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $3.52B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGB trades at $8.56, down 1.72% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue projected to grow from $673M in 2025 to $985M in 2026, turning from a net loss of $30M to a $16M profit. Recent copper production announcements highlight operational strength, though valuation metrics remain elevated with a P/E of 406.88. Analyst sentiment is mixed with a 25% buy rating amid balanced hold/sell recommendations.
The outlook for TGB hinges on copper production growth from Gibraltar and Florence mines, supporting revenue expansion and margin improvement. Key risks include execution challenges in mine ramp-ups, commodity price volatility, and high debt levels. While technical indicators suggest near-term upside, the stock's rich valuation requires careful monitoring of earnings delivery against expectations.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Trekor Metals Limited Common Shares
Trekor Metals is a mining company focused on copper. It operates the Gibraltar Mine and develops projects involving copper, gold, silver, and niobium.
Read more on TGB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
